Dactinomycin and Metastasis - a phase IV clinical study of FDA data

Summary:

Metastasis is reported as a side effect among people who take Dactinomycin (dactinomycin), especially for people who are female, 30-39 old, also take Etoposide, and have Wilms tumor.

The phase IV clinical study analyzes which people have Metastasis when taking Dactinomycin. It is created by eHealthMe based on reports of 2,575 people who have side effects when taking Dactinomycin from the FDA, and is updated regularly.

What is Dactinomycin?

Dactinomycin has active ingredients of dactinomycin. eHealthMe is studying from 2,577 Dactinomycin users. Check the latest studies of Dactinomycin.

What is Metastasis?

Metastasis (spreadable cancer to other organ from origin) is found to be associated with 544 drugs and 838 conditions by eHealthMe. Check the latest studies of Metastasis.

On Jul, 15, 2026

2,575 people reported to have side effects when taking Dactinomycin.
Among them, 17 people (0.66%) have Metastasis.

Among these 17 people:

What is the gender of people who have Metastasis when taking Dactinomycin? *

female: 58.33 %
male: 41.67 %

What is the age of people who have Metastasis when taking Dactinomycin? *

What are other drugs people take besides Dactinomycin? *

Tacrolimus: 3 people, 17.65%
Prednisone: 3 people, 17.65%
Mycophenolate Mofetil: 3 people, 17.65%
Melphalan Hydrochloride: 3 people, 17.65%
Heparin: 3 people, 17.65%
Etoposide: 3 people, 17.65%
Cyclophosphamide: 2 people, 11.76%
Methotrexate: 1 person, 5.88%
Meropenem: 1 person, 5.88%
Mercaptopurine: 1 person, 5.88%

What are other side effects people have besides Metastasis? *

Wilms Tumor (cancer of the kidneys that typically occurs in children): 4 people, 23.53%
Skin Cancer: 3 people, 17.65%
Disease Recurrence: 3 people, 17.65%
Malignant Neoplasm Progression (cancer tumour came back): 3 people, 17.65%
Malignant Soft Tissue Neoplasm (cancer tumour of soft tissue): 3 people, 17.65%
Neoplasm Progression (growth of tumour): 3 people, 17.65%
Metastases To Peritoneum (cancer spreads to peritoneum): 2 people, 11.76%
Metastases To Lymph Nodes (cancer spreads to lymph node): 2 people, 11.76%
Mucosal Inflammation (infection of mucous membrane): 1 person, 5.88%
Mucoepidermoid Carcinoma (cancer of type of salivary gland malignancy in adults): 1 person, 5.88%

What are the existing conditions these people have? *

Wilms Tumor (cancer of the kidneys that typically occurs in children): 7 people, 41.18%
Skin Cancer: 2 people, 11.76%
Ewing's Sarcoma (malignant small, round, blue cell tumour): 2 people, 11.76%
Rhabdomyosarcoma (cancer of the bone, soft tissues, or connective tissue (e.g., tendon or cartilage)): 1 person, 5.88%
Malignant Soft Tissue Neoplasm (cancer tumour of soft tissue): 1 person, 5.88%
Immunodeficiency Disorders: 1 person, 5.88%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Dactinomycin and have Metastasis?

- Check whether Metastasis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Dactinomycin:

Dactinomycin (2,577 reports)

Metastasis treatments and more:

Metastasis (11,222 reports)

Browse all side effects of Dactinomycin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Metastasis:

Metastasis (544 drugs)

Browse all the conditions that are associated with Metastasis:

Metastasis (838 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on dactinomycin (the active ingredients of Dactinomycin) and Dactinomycin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.